Recent developments include the commercial launch of the Pivot insulin delivery system in the U.S., a $3.4 million stock offering, issuance of a new U.S. patent, and insider share purchases.

• Modular Medical announced commercial availability and commenced initial shipments of its Pivot insulin delivery system in the United States in June 2026, with plans to expand commercial activities across metropolitan markets by late 2026 [S1].
• The company priced a $3.4 million stock offering at $4.50 per share in April 2026 [N2].
• Modular Medical was issued a new U.S. patent for its pairing technology in February 2024 [N7].
• The CEO purchased 156,250 shares in an insider transaction in March 2025 [N8].
• The company sponsored the inaugural ADEPT conference in November 2024, indicating engagement with the diabetes care community [N7].

Modular Medical's innovative Pivot pump addresses key barriers to insulin pump adoption by offering a simpler, more affordable, and user-friendly device. Its FDA clearance and initial commercial shipments mark important milestones toward market penetration. The company's focus on the large 'Almost Pumpers' segment, including both Type 1 and Type 2 diabetes patients, represents a substantial market opportunity. Planned enhancements such as automated insulin delivery and integration with glucose monitors could broaden its appeal. The company's efforts to secure insurance reimbursement and expand internationally through CE mark clearance may further support adoption and revenue growth.

Modular Medical faces significant risks including substantial doubt about its ability to continue as a going concern due to recurring operating losses and cash burn, necessitating additional capital raises that may dilute shareholders. The company operates in a highly competitive market dominated by established players with greater financial resources and market presence. Regulatory, reimbursement, and market acceptance challenges remain, and the company has yet to demonstrate sustained commercial success. Failure to secure sufficient financing or achieve meaningful market penetration could adversely affect its business and financial condition.

Modular Medical's moat lies in its innovative insulin pump technology that simplifies use through a tubeless, reusable patch pump design with a streamlined user interface and reduced complexity. Its focus on affordability and insurance reimbursement support aims to lower barriers for a large segment of insulin-requiring patients who have not adopted pumps due to cost and complexity. The company's proprietary pumping mechanism and modular design, along with plans for advanced features like automated insulin delivery and continuous glucose monitor integration, contribute to its differentiation. However, it competes against well-established companies with greater resources and market share, which presents challenges to building a durable competitive advantage.

• Going Concern Risk: The company has substantial doubt about its ability to continue as a going concern due to expected operating losses and cash burn, requiring additional capital raises to fund operations. Failure to raise sufficient capital could lead to curtailing operations or termination.
• Competitive Risk: Modular Medical competes against large, established insulin pump manufacturers with greater financial resources, experience, and market share, which may limit its ability to gain market acceptance.
• Regulatory and Reimbursement Risk: The company must obtain and maintain regulatory approvals and insurance coverage to commercialize its products successfully. Changes in reimbursement policies or failure to secure coverage could impact sales.
• Market Adoption Risk: The company targets a segment of patients deterred by current pump complexity and cost, but overcoming entrenched user habits and clinician preferences presents challenges.

• Modular Medical, Inc. is a medical device company focused on designing, developing, and commercializing innovative insulin pumps using modernized technology to increase pump adoption in the diabetes market.
• The company has developed a two-part patch pump system aimed at simplifying insulin pump use and expanding adoption beyond highly motivated users to a broader mass market, including both Type 1 and Type 2 diabetes patients requiring multiple daily insulin doses.
• The initial product, MODD1, received FDA 510(k) clearance in September 2024 but is not intended for commercialization.
• The company developed a next-generation tubeless patch pump called Pivot, which integrates the infusion set under the removable pump into a true tubeless patch.
• Pivot received FDA clearance in April 2026 and began initial commercial shipments in the United States in June 2026, with plans to expand commercial activities across metropolitan markets by late 2026.
• The company intends to obtain CE mark clearance for Pivot by the second quarter of 2027 to enable marketing and sales in Europe and other international markets.
• Modular Medical aims to address shortcomings of existing insulin pumps, including complexity, bulkiness, cost, outdated design, and pump mechanism limitations, to increase adoption among 'Almost Pumpers'—patients aware of pumps but deterred by current product issues.
• The Pivot pump features a three-part system (one reusable, two disposable), one-button interface, optional phone software, 90-day reusable pump with 3-day disposable cartridges, no external controller, no charging or battery replacement, and a slim, lightweight profile.
• The company targets a large market opportunity, with approximately 4.2 million potential insulin pump users in the U.S. split evenly between Type 1 and Type 2 diabetes, and estimates a $3 billion addressable market based on prescription cartridge revenue.
• Modular Medical's business model includes focusing on affordability, ease of use, insurance reimbursement support, patient education, and service to overcome barriers to insulin pump adoption.
• The company has a history of significant operating losses and an accumulated deficit of approximately $119.4 million as of June 30, 2026.
• As of June 30, 2026, Modular Medical had cash and cash equivalents of $3.92 million, current assets of $4.85 million, current liabilities of $1.49 million, a current ratio of 3.25, and a cash ratio of 2.63.
• The company reported a net loss of $6.49 million and basic and diluted EPS of -$1.19 for the quarter ended June 30, 2026.
• Modular Medical completed a registered direct offering in April 2026 raising approximately $3.0 million and received net proceeds of $0.7 million from at-the-market sales in June 2026, with additional proceeds of $5.1 million from at-the-market sales after June 30, 2026.
• The company faces substantial doubt about its ability to continue as a going concern due to expected operating losses and cash burn, requiring additional capital raises to fund operations.
• Modular Medical competes with established insulin pump manufacturers such as Insulet, Tandem Diabetes Care, and Minimed, which hold significant U.S. market shares and have greater financial resources and experience.
• The company plans to evolve the Pivot pump with future features including phone-based control, Alternative Controller Enabled (ACE) and Automated Insulin Delivery (AID) capabilities, and integration with continuous glucose monitors to expand its market.
• Recent news includes a $3.4 million stock offering priced at $4.50 per share in April 2026, initial commercial availability and shipments of the Pivot pump in June 2026, and the issuance of a new U.S. patent for its pairing technology in February 2024.
• The CEO made an insider purchase of 156,250 shares in March 2025, indicating insider confidence.
• The company sponsored the inaugural ADEPT conference in November 2024, indicating engagement with the diabetes care community.